Elotuzumab as a novel anti-myeloma immunotherapy

• Egile Nagusiak: Sabarinath Venniyil Radhakrishnan (Egilea), Neelam Bhardwaj (Egilea), Mary Steinbach (Egilea), Janet Weidner (Egilea), Tim Luetkens (Egilea), Djordje Atanackovic (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2017-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...